🫀 Semaglutide for Obesity—Cochrane Review: Sustained, Clinically Relevant Weight Loss, CV Signal Confirmed
🔥 Main in 3 points
- Semaglutide ensures robust weight loss vs placebo: mean difference (MD) –10.73% at 6–17 months (high-certainty).
- Reduces risk for MACE (RR 0.63, 95% CI 0.44–0.90) and mortality (RR 0.69, 95% CI 0.48–0.98), though absolute benefits are modest.
- Increases mild/moderate GI adverse events and withdrawals (long-term: RR for withdrawal 2.03) but not serious AEs.
🧪 Context
Cochrane meta-analysis of 18 RCTs (n = 27,949; mean age 41–69.5; avg BMI 32–40.3) assessed semaglutide vs placebo for adults with obesity (≥6 months). Additional comparators: liraglutide, tirzepatide.
📍 Practical significance
Semaglutide remains the most evidence-backed GLP-1RA for sustained weight reduction and reduction in CV events/mortality in obesity, independent of baseline risk. GI AEs and treatment discontinuation remain principal limiting factors—counsel on titration and expectations. Await further independent/long-term safety data.
🔗 Source
PubMed | DOI
🧪 SELECT Trial: Semaglutide CV Protection Is Independent of Baseline Adiposity
🩸 What was studied
Prespecified subanalysis of SELECT RCT (n = 17,604; age ≥45; BMI ≥27; CV disease, no diabetes): semaglutide 2.4 mg weekly vs placebo; outcome—major adverse CV events (MACE) by baseline and changes in bodyweight/waist circumference.
📈 Key results
- Semaglutide reduced MACE across all baseline adiposity (HR ~0.96 per –5kg/–5cm WC).
- Weight loss per se did not explain MACE benefit, but WC reduction did: 33% of MACE reduction mediated by WC change.
- In placebo, weight loss paradoxically associated with ↑MACE risk.
📍 What this changes in practice
Semaglutide's cardioprotective effect in overweight/obese patients is largely independent of weight loss, with a modest additional benefit from waist reduction. Reinforce semaglutide's role in high CV risk obesity—do not restrict to those with severe adiposity.
🔗 Source
PubMed | DOI
🧾 Semaglutide in Type 1 Diabetes: Insulin Pump Dosing Requires Early, Ongoing Adjustment
✅ Do
- Expect rapid reduction in total/bolus insulin needs by day 7 of semaglutide initiation; reduce carbohydrate inputs accordingly.
- Monitor and adjust basal by day 32, with ongoing titration of pump parameters.
⚠️ With caution
- Even with CGM/AID tech, individualized pump setting changes are essential to avoid hypoglycemia.
- Maintain close follow-up during early dose titration phase.
🔗 Source
PubMed | DOI
⚠️ Perioperative Aspiration Risk: Residue-Free Diet and GLP-1RA Withdrawal May NOT Prevent Complications
🧪 Context
Case report: 61F, elective angiography on weekly semaglutide for weight loss (discontinued 6 days before procedure), otherwise abided by 24h residue-free diet/12h fasting.
📊 Numbers
Despite protocol adherence, large-volume aspiration occurred during induction. Prior semaglutide use undisclosed.
📍 Actions
- Intensify perioperative screening: proactively ask, document GLP-1RA use.
- Consider interruption intervals >7 days for elective procedures.
- Routinely use bedside gastric ultrasound before anesthesia on known/suspected GLP-1RA users.
🔗 Source
PubMed | DOI
🩸 Real-World Data: Semaglutide vs Standard of Care for Glycemic Control
🔥 Main in 3 points
- Propensity-matched RWE cohort (n = 1,144 pairs): semaglutide initiators were 30% more likely to achieve HbA1c <7% vs SoC ( risk ratio 1.30 [1.16–1.45]).
- A1c reduction: –1.3% with semaglutide vs –1.1% with SoC.
- Results closely mirrored interim SEPRA phase IV RCT.
🧪 Context
Adults with T2D on metformin, starting injectable semaglutide or SoC (DPP4, SGLT2, SU, other GLP-1RA), using large national claims data.
📍 Practical significance
Supports semaglutide’s real-world advantage for glycemic control after metformin. Fit-for-purpose RWE studies can complement RCTs in rapid comparative effectiveness evaluations.
🔗 Source
PubMed | DOI
🛡️ GLP-1RA Reduces Aortic Dilatation Progression in T2DM—Vasoprotective Beyond Glycemic Control
🧪 What was studied
Prospective study (n = 127 T2DM with subclinical ascending aortic dilatation): GLP-1RA (liraglutide, semaglutide, dulaglutide) vs standard care over 24 months.
📈 Key results
- Aorta dilatation progression significantly less with GLP-1RA: +0.36mm vs +1.05mm (p<0.001).
- Favorable biomarker shifts (↓MMP-9, CRP; ↑TIMP-1, OPG).
- GLP-1RA use was an independent predictor of reduced aortic dilatation.
📍 What this changes in practice
GLP-1RA therapy may confer vascular protection in T2DM with subclinical aortic dilatation. Consider for patients at risk of aortic disease as additional benefit.
🔗 Source
PubMed | DOI
📈 GLP-1RA in Craniopharyngioma-Associated Hypothalamic Obesity: Semaglutide Is Effective but Requires Endocrine Vigilance
🧪 What was studied
Multicentre RWE study (n = 116 adults post-craniopharyngioma, hypothalamic obesity; mean BMI 40), >44 months follow-up.
📈 Key results
- Mean WL: –4.6% (high interindividual variability); 51% had ≥5% WL, 28% had ≥10% WL.
- Semaglutide yielded greatest WL (–6.8%; –8.5% for nondiabetics).
- 12% adrenal/10% vasopressin deficiency decompensations; 13% stopped due to GI intolerance.
📍 What this changes in practice
GLP-1RAs (esp. semaglutide) offer modest benefits in hypothalamic obesity post-CP, but require diligent endocrine surveillance for adrenal/vasopressin balance and GI AEs—integrate close monitoring into practice.
🔗 Source
PubMed | DOI
|
